Evidence map›Paper›PMID 34681607›Full record

ArticleInternational journal of molecular sciences2021

PACAP and VIP Modulate LPS-Induced Microglial Activation and Trigger Distinct Phenotypic Changes in Murine BV2 Microglial Cells.

Jocelyn Karunia, Aram Niaz, Mawj Mandwie, Sarah Thomas Broome, Kevin A Keay, James A Waschek, Ghaith Al-Badri, Alessandro Castorina

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Gut neuropeptide involvement in Parkinson's disease.American journal of physiology. Gastrointestinal and liver physiology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jocelyn KaruniaLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Aram NiazLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0001-6636-2555
Mawj MandwieLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-4165-4276
Sarah Thomas BroomeLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-5444-0920
Kevin A KeaySchool of Medical Science, [Neuroscience] and Brain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0003-3934-4380
James A WaschekIntellectual Development and Disabilities Research Centre, Semel Institute for Neuroscience and Human Behaviour/Neuropsychiatric Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.
Ghaith Al-BadriLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Alessandro CastorinaLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0001-7037-759X
University of Technology Sydney · AUThe University of Sydney · AUUniversity of California, Los Angeles · US

Funding

Rebecca L. Cooper Medical Research Foundation PRO19-8734
6 · The paper itself

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are two structurally related immunosuppressive peptides. However, the underlying mechanisms through which these peptides regulate microglial activity are not fully understood. Using lipopolysaccharide (LPS) to induce an inflammatory challenge, we tested whether PACAP or VIP differentially affected microglial activation, morphology and cell migration. We found that both peptides attenuated LPS-induced expression of the microglial activation markers

Indexed as

AnimalsCalcium-Binding ProteinsCell LineCell MovementGene ExpressionInterleukin-1betaInterleukin-6LipopolysaccharidesMiceMicrofilament ProteinsMicrogliaNitric Oxide Synthase Type IINitritesPhenotypePituitary Adenylate Cyclase-Activating PolypeptideUrokinase-Type Plasminogen ActivatorAdcyap1 protein, mouseAif1 protein, mouseCalcium-Binding ProteinsInterleukin-1betaInterleukin-6LipopolysaccharidesMicrofilament ProteinsNitric Oxide Synthase Type IINitritesPituitary Adenylate Cyclase-Activating PolypeptideUrokinase-Type Plasminogen ActivatorVasoactive Intestinal PeptideBV2GFAPIba1inflammatory markersmicroglial activationmorphological analysesPACAPVIP

Identifiers

PMID34681607
PMCPMC8535941
OpenAlexW3206850514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.